UNICHEMLABBSEUnichem Laboratories LtdMediumNeutral
Announced Fri, 22 May · 16:42 IST

Outcome of Board Meeting

Management Changes View source PDF

UNICHEMLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-4.7%1-day move
₹372.60
prior close
₹361.05
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.4-0.9-1.0-0.8-4.7-5.2-6.1-8.9-1.8-0.9+19.8+16.1+45.0
Up moveDown movePending
AI summary

Unichem Laboratories Board approved redesignation of Mr. Pabitrakumar Bhattacharyya from Managing Director to Managing Director & Chief Executive Officer effective 22nd May 2026. He was also re-appointed as MD & CEO for three years (10th August 2026 to 9th August 2029), subject to shareholder approval. Consolidated revenue for FY2026 stood at Rs 2,201.85 crore with PAT of Rs 252.84 crore, compared to Rs 2,110.97 crore and Rs 137.52 crore respectively in FY2025. Standalone revenue declined to Rs 1,412.29 crore from Rs 1,735.70 crore. Exceptional items included Rs 275.52 crore gain from land disposal, Rs 58.26 crore EU fine interest, partially offset by Rs 15.40 crore labour code implementation cost. Cost auditors and internal auditors were re-appointed for FY2026-27.

Likely market impact

The CEO consolidation into one role provides leadership stability ahead of his new three-year term. Strong consolidated profitability with exceptional gains masks standalone revenue decline. Sale of Ireland subsidiary completes earlier restructuring.